ArticleAmerican journal of obstetrics and gynecology2017
Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia.
Article in American journal of obstetrics and gynecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Pooled it
- Magnesium Supplementation and Blood Pressure in Pregnancy: A Double-Blind Randomized Multicenter Study.Journal of pregnancy · 2018Trial
- Disparities in low-dose aspirin prescription among patients at risk for preeclampsia.Pregnancy (Hoboken, N.J.) · 2026Article
- Aberrant Uteroplacental and Vascular Signaling and Remodeling by Matrix Metalloproteinases in Pregnancy-Related Hypertension and Preeclampsia.Biomolecules · 2026Review
- Closing the Gap Between Recommendation and Uptake: Provider Communication About Low-Dose Aspirin for Preeclampsia Prevention.Journal of pediatrics, perinatology and child health · 2026Article
- Chronic hypertension diagnosed in a previous pregnancy is associated with recurrent preeclampsia.Clinical hypertension · 2026Article
- Preventing Preeclampsia With Low-Dose Aspirin: A Systematic Review of Efficacy Across Diverse Populations.Cureus · 2025Review
- The Role of Race in Pregnancy, Hypertension, and Long-Term Outcomes.Current cardiology reports · 2025Review
- Elevated Micro- and Nanoplastics Detected in Preterm Human Placentae.Research square · 2025Article
- Leveraging quality improvement to promote health equity: standardization of prenatal aspirin recommendations.BMC pregnancy and childbirth · 2023Article
- Article
- Impact of Aspirin Supplementation for Pre-Eclampsia Prevention on Neonatal Outcomes.Kansas journal of medicine · 2023Article
- Improving preeclampsia risk prediction by modeling pregnancy trajectories from routinely collected electronic medical record data.NPJ digital medicine · 2022Article
- Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study.American journal of perinatology · 2021Article
- Active Management Reduces the Incidence of Recurrent Pre-eclampsia and Improves Maternal and Fetal Outcomes in Women With Recurrent Pre-eclampsia.Frontiers in medicine · 2021Article
- Comparative risks and predictors of preeclamptic pregnancy in the Eastern, Western and developing world.Biochemical pharmacology · 2020Review
- Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial.American journal of obstetrics and gynecology · 2020Article
- Insurance Differences in Preventive Care Use and Adverse Birth Outcomes Among Pregnant Women in a Medicaid Nonexpansion State: A Retrospective Cohort Study.Journal of women's health (2002) · 2020Article
- Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage.British journal of clinical pharmacology · 2020Review
- Complications in pregnant women with sickle cell disease.Hematology. American Society of Hematology. Education Program · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe US Preventive Services Task Force recommends low-dose aspirin for the prevention of preeclampsia among women at high risk for primary occurrence or recurrence of disease. Recommendations for the use of aspirin for preeclampsia prevention were issued by the US Preventive Services Task Force in September 2014.
objectivesThe objective of the study was to evaluate the incidence of recurrent preeclampsia in our cohort before and after the US Preventive Services Task Force recommendation for aspirin for preeclampsia prevention. STUDY
designThis was a retrospective cohort study designed to evaluate the rates of recurrent preeclampsia among women with a history of preeclampsia. We utilized a 2-hospital, single academic institution database from August 2011 through June 2016. We excluded multiple gestations and included only the first delivery for women with multiple deliveries during the study period. The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations. Potential confounders were accounted for in multivariate analyses, and relative risk and adjusted relative risk were calculated.
resultsA total of 17,256 deliveries occurred during the study period. A total of 417 women had a documented history of prior preeclampsia: 284 women before and 133 women after the US Preventive Services Task Force recommendation. Comparing the before and after groups, the proportion of Hispanic women in the after group was lower and the method of payment differed between the groups (P <.0001). The prevalence of type 1 diabetes was increased in the after period, but overall rates of pregestational diabetes were similar (6.3% before vs 5.3% after [P > .05]). Risk factors for recurrent preeclampsia included maternal age >35 years (relative risk, 1.83; 95% confidence interval, 1.34-2.48), Medicaid insurance (relative risk, 2.08; 95% confidence interval, 1.15-3.78), type 2 diabetes (relative risk, 2.13; 95% confidence interval, 1.37-3.33), and chronic hypertension (relative risk, 1.96; 95% confidence interval, 1.44-2.66). The risk of recurrent preeclampsia was decreased by 30% in the after group (adjusted relative risk, 0.70; 95% confidence interval, 0.52-0.95).
conclusionRates of recurrent preeclampsia among women with a history of preeclampsia decreased by 30% after release of the US Preventive Services Task Force recommendation for aspirin for preeclampsia prevention. Future prospective studies should include direct measures of aspirin compliance, gestational age at initiation, and explore the influence of race and ethnicity on the efficacy of this primary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.